Crinetics Pharmaceuticals, Inc. (CRNX) Cash Flow Statement

The OCF/NI ratio has hovered between 0.64 and 0.98 over the last ten quarters, with the most recent quarter at 0.78. This suggests that a significant portion of net losses is non-cash, primarily stock-based compensation, which totaled $24.9M in 2026Q2. Investors should monitor whether this gap narrows as SBC becomes a smaller proportion of total expenses, which would indicate a more cash-intensive burn rate.

The FCF margin, though distorted by milestone revenue, has remained deeply negative, with the most recent quarter at -3.8% due to a revenue spike. Excluding that anomaly, FCF margins have consistently been in the -80% to -780% range, underscoring the pre-commercial stage. The trajectory suggests that cash burn will continue to escalate as the company advances toward NDA submission and potential launch, making external financing a near-term necessity.

CapEx/Revenue ratios have ranged from 2.1% to 7.6%, but given the minimal revenue base, absolute CapEx is immaterial. This suggests that the company's cash burn is driven almost entirely by operating expenses, particularly R&D and SG&A, rather than capital investment. The lack of significant CapEx implies that future growth will not require substantial fixed asset outlays, but the need for working capital and clinical trial funding will persist.

The working capital changes are relatively small compared to the overall burn, but they can cause quarterly fluctuations in operating cash flow. For instance, the -$26.2M change in 2026Q1 likely reflects an increase in receivables or prepaid expenses related to trial activities. Investors should not over-interpret these swings as they are typical for a clinical-stage biotech and do not signal a fundamental change in cash generation.

The absence of capital returns is expected for a clinical-stage company, but the cash burn rate of approximately $100M per quarter implies that the current cash position provides less than one year of runway. This suggests that management will likely need to raise capital through equity offerings or partnerships, which could be dilutive to existing shareholders. The lack of acquisition activity also indicates a focus on internal pipeline development.

The cumulative gap of approximately $187M between net income and operating cash flow is primarily attributable to stock-based compensation, which totaled over $200M in the same period. This divergence suggests that while the company is burning cash at a rapid pace, the economic cost to shareholders is partially offset by the non-cash nature of SBC. However, the cash burn remains substantial and is the primary driver of the company's financing needs.